pharmaceutical · input

Generic Oncology Injectable Vials (Cisplatin, Carboplatin, Paclitaxel)

Finished-dose sterile injectable vials of platinum-based and taxane chemotherapy agents used in cancer infusion centers and hospitals: cisplatin injection (1mg/mL), carboplatin injection (10mg/mL), paclitaxel injection (6mg/mL), oxaliplatin injection, and gemcitabine injection. Distinct from the APIs — these are the finished, sterile-filled vials ready for patient administration. Market concentration: Pfizer/Hospira, Hikma (Columbus OH), Fresenius Kabi, Teva, and Mylan/Viatris supply the vast majority of US hospital volume. The 2023 Intas API shortage cascaded into these finished-dose vials as well.

Source countries

Companies

Goods affected

Claims on record

Who makes it

Supplier companies

2 companies produce generic oncology injectable vials (cisplatin, carboplatin, paclitaxel).

Hikma Pharmaceuticals PLC(HIK.L)

HQ JO20% share

Hikma Pharmaceuticals PLC (Amman Jordan; London Stock Exchange: HIK; NYSE: WHL; ~$3.1B revenue) is a major US generic injectable pharmaceutical manufacturer primarily through its Hikma Pharmaceuticals USA (formerly Roxane Laboratories) division acquired in 2016 for $2.65B. US injectable manufacturing: Columbus OH (Hikma Columbus — formerly Roxane; large sterile injectable campus) and Eatontown NJ (Hikma Eatontown). Hikma produces morphine sulfate injection, fentanyl citrate injection, and hydromorphone HCl injection as Schedule II controlled substance generics for US hospitals. Hikma is the largest pure-play injectable pharmaceutical company by volume in the US generics market. Jordan-headquartered and London-listed but the business is majority US generic injectables — an unusual corporate structure for what is effectively a critical US hospital drug supplier.

Fresenius Kabi (injectable opioids)(FRE.DE)

HQ DE18% share

← Browse the supply map